Expert Opinion

Welcome US Patent & Trademark Office | Log in | Register

Home Browse Search Subscribe Reprints About My Profil

Journals
Expert Opinion series
Services
Register
Information for authors
Information for librarians
Free trial
TOC alert service
Supplements
Reprints
Contact
FAQ
Help

Search Results: 212 matches found
Search Query: **All**: src inhibitor clinic

Results page 1 of 22
Order results: ○ by date ◉ by relevancy | Display snippets: ○ y

Add to favourite | View summaries | Download to citation manager
☐ To select/unselect all items click here

☐ 1. **Src inhibitors: genomics to therapeutics**
Tomi Sawyer, Brendan Boyce, David Dalgarno, John Iuliucci
Expert Opinion on Investigational Drugs, Jul 2001, Vol. 10, No. 7 1344.
Summary | PDF (361 KB) | PDF Plus (462 KB) | Add to Favorites

☐ 2. **Methylenedioxyanilino-quinazolines and -cyanoquinolines MEK and/or Src**
Expert Opinion on Therapeutic Patents, Jul 2004, Vol. 14, No. 7,
Summary | PDF (94 KB) | PDF Plus (118 KB) | Add to Favorites

☐ 3. **Src kinases as targets for Bcell acute lymphoblastic leuka**
Shaoguang Li
Expert Opinion on Therapeutic Targets, Apr 2005, Vol. 9, No. 2,
Summary | PDF (149 KB) | PDF Plus | Add to Favorites | Relatec

☐ 4. **Small molecule tyrosine kinase inhibitors: clinical develop anticancer agents**
A Douglas Laird, Julie M Cherrington
Expert Opinion on Investigational Drugs, Jan 2003, Vol. 12, No.
Summary | PDF (298 KB) | PDF Plus (361 KB) | Add to Favorites

☐ 5. **Novel therapies for osteoporosis**
Diane M Biskobing
Expert Opinion on Investigational Drugs, Apr 2003, Vol. 12, No.
Summary | PDF (189 KB) | PDF Plus (251 KB) | Add to Favorites

☐ 6. **Patent focus on agents for osteoporosis: September 1999**
Laura D Gegnas

Expert Opinion on Therapeutic Patents, Jun 2000, Vol. 10, No. 6
Summary | PDF (130 KB) | PDF Plus (154 KB) | Add to Favorites

---

☐ 7. **Inhibitors of protein-protein interactions**
Thomas R Gadek, Denise A Ockey
Expert Opinion on Therapeutic Patents, Mar 2002, Vol. 12, No. 3
Summary | PDF (138 KB) | PDF Plus (160 KB) | Add to Favorites

---

☐ 8. **CDK inhibitors in clinical development for the treatment o**
Peter M Fischer, Athos Gianella-Borradori
Expert Opinion on Investigational Drugs, Jun 2003, Vol. 12, No.
Summary | PDF (450 KB) | PDF Plus (540 KB) | Add to Favorites

---

☐ 9. **Selective tyrosine kinase inhibitors**
Sandra E Wilkinson, William Harris
Expert Opinion on Emerging Drugs, Oct 2000, Vol. 5, No. 3, Pag
Summary | PDF (87 KB) | PDF Plus (112 KB) | Add to Favorites

☐ 10. **PDE4 inhibitors and chronic obstructive pulmonary disea**
Sharon L Wolda
Expert Opinion on Emerging Drugs, Oct 2000, Vol. 5, No. 3, Pa
Summary | PDF (103 KB) | PDF Plus (123 KB) | Add to Favorite

Results page 1 of 22

Ashley Publications, Telephone House, 69-77 Paul Street, London, EC2A 4LC
Tel: +44 (0)20 7017 5000 · Fax: +44 (0)20 7017 7667

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	665	((514/262.1) or (544/256)).CCLS.	US-PGPUB; USPAT	OR	OFF	2005/08/31 16:54
L2	10	1 and ("[4,5-d]" "(4,5-d)" "4,5-d")	US-PGPUB; USPAT	OR	ON	2005/08/31 16:54

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS	29	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	30	AUG 30	CASREACT - Enhanced with displayable reaction conditions

```
 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:38:44 ON 31 AUG 2005

=> file reg
FILE 'REGISTRY' ENTERED AT 13:38:55 ON 31 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 AUG 2005  HIGHEST RN 862155-39-3
DICTIONARY FILE UPDATES:  30 AUG 2005  HIGHEST RN 862155-39-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html
```

=>
Uploading c:\program files\stnexp\queries\10689235a.str



chain nodes :
23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
2-24 4-27 11-24 14-20 19-25 19-26 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-19 6-22 7-8 7-12 8-9 9-10 10-11 11-12 13-14
13-18 14-15 15-16 16-17 17-18 19-20 20-21 21-22
exact/norm bonds :
2-24 5-19 6-22 11-24 14-20 20-21 21-22 21-23
exact bonds :
4-27 19-20 19-25 19-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=>
Uploading c:\program files\stnexp\queries\10689235.str



chain nodes :
23 24 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
2-24 4-28 11-24 14-20 19-26 19-27 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-19 6-22 7-8 7-12 8-9 9-10 10-11 11-12 13-14
13-18 14-15 15-16 16-17 17-18 19-20 20-21 21-22
exact/norm bonds :
2-24 5-19 6-22 11-24 14-20 19-26 20-21 21-22 21-23
exact bonds :
4-28 19-20 19-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18

G1:H,CH3,Et

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 26:CLASS 27:CLASS 28:CLASS

L2 STRUCTURE UPLOADED

=> d l1 sim; d l2 sim; s l2
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L2 HAS NO ANSWERS
L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

SAMPLE SEARCH INITIATED 13:40:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 38 TO ITERATE

100.0% PROCESSED 38 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 391 TO 1129
PROJECTED ANSWERS: 93 TO 587

L3 17 SEA SSS SAM L2

=> d scan

L3 17 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(4-chloro-2-fluorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-[(1R)-2-hydroxy-1-methylethyl]-4-methyl-, (4S)- (9CI)
MF C22 H20 Cl F2 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 subset = l3 sample
SAMPLE SUBSET SEARCH INITIATED 13:40:52 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 93 TO 587
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 80 TO 560

L4 16 SEA SUB=L3 SSS SAM L1

=> d scan

L4 16 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-[3-[7-[[3-[(2-aminoethyl)amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI)
MF C30 H29 F3 N8 O2

PAGE 1-A



PAGE 1-B

—CF_3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l2 full; s l1 subset = l5, s l5 not l6; file caplus; s wo20040041822?/pn
FULL SEARCH INITIATED 13:42:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 845 TO ITERATE

100.0% PROCESSED 845 ITERATIONS 435 ANSWERS
SEARCH TIME: 00.00.01

L5 435 SEA SSS FUL L2

L6 NOT FOUND
COMMAND STACK INTERRUPTED. ENTER "DISPLAY HISTORY"
TO SEE WHICH COMMANDS WERE EXECUTED.

The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l1 subset = l5; s l5 not l6; file caplus; s wo20040041822?/pn
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 13:43:31 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 435 TO ITERATE

100.0% PROCESSED 435 ITERATIONS 387 ANSWERS
SEARCH TIME: 00.00.01

L6 387 SEA SUB=L5 SSS FUL L1

L7 48 L5 NOT L6

```
FILE 'CAPLUS' ENTERED AT 13:43:31 ON 31 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 31 Aug 2005  VOL 143 ISS 10
FILE LAST UPDATED: 30 Aug 2005  (20050830/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


L8            1 WO20040041822?/PN
                (WO2004041822/PN)

=> s l7
L9            3 L7

=> s l9 not l8
L10           2 L9 NOT L8

=> sort py l10
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L10
L11           2 SORT L10 PY

=> d 1-2 ibib fhitstr

L11  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:412945  CAPLUS
DOCUMENT NUMBER:          140:423693
TITLE:                    Preparation of pyrimido Src tyrosine kinase inhibitors
                          as anti-proliferative agents for the treatment of
                          cancer
INVENTOR(S):              Luk, Kin-Chun; Rossman, Pamela Loreen; Scheiblich,
                          Stefan; So, Sung-Sau
PATENT ASSIGNEE(S):       F. Hoffmann-La Roche A.-G., Switz.
SOURCE:                   PCT Int. Appl., 59 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041821	A1	20040521	WO 2003-EP311892	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110773	A1	20040610	US 2003-689438	20031020
US 2005075272	A1	20050407	US 2003-689235	20031020
CA 2502180	AA	20040521	CA 2003-2502180	20031027
EP 1560829	A1	20050810	EP 2003-758072	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-423670P P 20021104
WO 2003-EP11892 W 20031027

OTHER SOURCE(S): MARPAT 140:423693

IT **690995-25-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimido Src tyrosine kinase inhibitors as anti-proliferative agents for the treatment of cancer)

RN 690995-25-6 CAPLUS

CN Benzonitrile, 3-[7-[[3-[2-(dimethylamino)ethyl]phenyl]amino]-3,4-dihydro-3-(4-methoxyphenyl)-4-methyl-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:372873 CAPLUS

DOCUMENT NUMBER: 140:391294

TITLE: Preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives as inhibitors of src family tyrosine kinases

INVENTOR(S): Cai, Jianping; Dimoudis, Nikolaos; Honold, Konrad; Luk, Kin-Chun; Scheiblich, Stefan; Sudergat, Hilke; Tiefenthaler, Georg; Tonn, Oliver

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087600	A1	20040506	US 2003-697543	20031030
CA 2502477	AA	20040521	CA 2003-2502477	20031103
WO 2004041823	A1	20040521	WO 2003-EP12203	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1560831	A1	20050810	EP 2003-779831	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: EP 2002-24573 A 20021104
WO 2003-EP12203 W 20031103

OTHER SOURCE(S): CASREACT 140:391294; MARPAT 140:391294

IT **686757-17-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)

RN 686757-17-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[(2,3-dihydro-4,4-dioxido-1,4-benzoxathiin-6-yl)amino]-3,4-dihydro-1,4-dimethyl-, (4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s l6
L12 7 L6

```
=> sort py l12
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L12
L13             7 SORT L12 PY

=> d 1-7 cbib pi fhitstr

L13  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2005 ACS on STN
1999:764041   Document No. 132:22971  Preparation of oxopyrido- and
     -pyrimidopyrimidines as cellular proliferation inhibitors.  Dobrusin,
     Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel
     Conrad; Showalter, Howard Daniel Hollis; Toogood, Peter; Trumpp-Kallmeyer,
     Susanne A. (Warner-Lambert Co., USA).  PCT Int. Appl. WO 9961444 A2
     19991202, 133 pp.  DESIGNATED STATES: W:  AE, AL, AU, BA, BB, BG, BR, CA,
     CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT,
     LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ,
     VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF,
     CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML,
     MR, NE, NL, PT, SE, SN, TD, TG.  (English).  CODEN: PIXXD2.  APPLICATION:
     WO 1999-US10187 19990510.  PRIORITY: US 1998-86708 19980526; US
     1999-126158 19990325.
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 9961444           A2    19991202    WO 1999-US10187        19990510
     WO 9961444           A3    20000203
         W:  AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU,
             ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO,
             NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2329703            AA    19991202    CA 1999-2329703        19990510
     AU 9940734            A1    19991213    AU 1999-40734          19990510
     AU 763839             B2    20030731
     BR 9911590            A     20010213    BR 1999-11590          19990510
     EP 1080092            A2    20010307    EP 1999-924165         19990510
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     TR 200003429          T2    20010723    TR 2000-200003429      19990510
     JP 2002516327         T2    20020604    JP 2000-550849         19990510
     EE 200000706          A     20020617    EE 2000-706            19990510
     NZ 508268             A     20040227    NZ 1999-508268         19990510
     ZA 2000006536         A     20020211    ZA 2000-6536           20001110
     BG 104960             A     20011031    BG 2000-104960         20001117
     HR 2000000799         A1    20010630    HR 2000-799            20001120
     NO 2000005928         A     20001123    NO 2000-5928           20001123
     HK 1039483            A1    20040618    HK 2001-107828         20011108
     US 2004044012         A1    20040304    US 2003-638848         20030811
IT   251370-13-5P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as
        inhibitors of cellular proliferation)
RN   251370-13-5  CAPLUS
CN   Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-
     tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI)  (CA
```

INDEX NAME)



L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
2000:291041 Document No. 132:308352 Preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors. Harris, William; Hill, Christopher Huw; Smith, Ian Edward David (F. Hoffmann-La Roche A.-G., Switz.). PCT Int. Appl. WO 2000024744 A1 20000504, 109 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP7675 19991013. PRIORITY: GB 1998-23277 19981023; GB 1999-20044 19990824.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024744	A1	20000504	WO 1999-EP7675	19991013
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2347474	AA	20000504	CA 1999-2347474	19991013
	BR 9914677	A	20010717	BR 1999-14677	19991013
	EP 1123295	A1	20010816	EP 1999-953796	19991013
	EP 1123295	B1	20040929		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101102	T2	20020121	TR 2001-200101102	19991013
	JP 2002528455	T2	20020903	JP 2000-578314	19991013
	JP 3593035	B2	20041124		
	NZ 510760	A	20030829	NZ 1999-510760	19991013
	AU 769989	B2	20040212	AU 2000-10363	19991013
	AT 277931	E	20041015	AT 1999-953796	19991013
	ES 2228123	T3	20050401	ES 1999-953796	19991013
	RU 2256662	C2	20050720	RU 2001-113444	19991013
	US 6150373	A	20001121	US 1999-422451	19991021
	ZA 2001002652	A	20020930	ZA 2001-2652	20010330

HR 2001000274	A1	20020630	HR 2001-274	20010412
NO 2001001929	A	20010419	NO 2001-1929	20010419
HK 1041483	A1	20041224	HK 2002-103084	20020424

IT **266312-86-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)
RN 266312-86-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
2004:857176 Document No. 141:350187 Preparation of pyrimido compounds having antiproliferative activity. Chen, Yi; Dermatakis, Apostolos; Liu, Jin-jun; Luk, Kin-chun; Michoud, Christophe; Rossman, Pamela Loreen (USA).
U.S. Pat. Appl. Publ. US 2004204427 A1 20041014, 55 pp. (English).
CODEN: USXXCO. APPLICATION: US 2004-817697 20040402. PRIORITY: US 2003-PV461694 20030410.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004204427	A1	20041014	US 2004-817697	20040402
WO 2004089955	A1	20041021	WO 2004-EP3447	20040401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **774232-16-5P**, 3-[3-(4-Methoxyphenyl)-2-oxo-7-phenylamino-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-1-yl]propionitrile
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrimido[4,5-d]pyrimidinones as selective inhibitors of both KDR and FGFR kinases)
RN 774232-16-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-1(2H)-propanenitrile, 3,4-dihydro-3-(4-methoxyphenyl)-2-oxo-7-(phenylamino)- (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
2004:372873 Document No. 140:391294 Preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives as inhibitors of src family tyrosine kinases. Cai, Jianping; Dimoudis, Nikolaos; Honold, Konrad; Luk, Kin-Chun; Scheiblich, Stefan; Sudergat, Hilke; Tiefenthaler, Georg; Tonn, Oliver (USA). U.S. Pat. Appl. Publ. US 2004087600 A1 20040506, 31 pp. (English). CODEN: USXXCO. APPLICATION: US 2003-697543 20031030. PRIORITY: EP 2002-24573 20021104.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004087600	A1	20040506	US 2003-697543	20031030
CA 2502477	AA	20040521	CA 2003-2502477	20031103
WO 2004041823	A1	20040521	WO 2003-EP12203	20031103

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1560831	A1	20050810	EP 2003-779831	20031103

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

IT **686756-87-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino-substituted dihydropyrimido[4,5-d]pyrimidinones as inhibitors of src family tyrosine kinases)

RN 686756-87-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-6-yl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
2004:162462 Document No. 140:199340 Preparation of pyrimidopyrimidinone derivatives having antiproliferative activity. Chen, Yi; Daniewski, Andrzej Robert; Harris, William; Kabat, Marek Michal; Liu, Emily Aijun; Liu, Jin-jun; Luk, Kin-chun; Michoud, Christophe (USA). U.S. Pat. Appl. Publ. US 2004038995 A1 20040226, 25 pp. (English). CODEN: USXXCO. APPLICATION: US 2003-623972 20030721. PRIORITY: US 2002-2002/PV403519 20020814.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004038995	A1	20040226	US 2003-623972	20030721
	CA 2494127	AA	20040304	CA 2003-2494127	20030807
	WO 2004018472	A2	20040304	WO 2003-EP8744	20030807
	WO 2004018472	A3	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	EP 1556384	A2	20050727	EP 2003-792269	20030807

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

IT **663198-02-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidopyrimidinone derivs. having antiproliferative activity)
RN 663198-02-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(4-methoxyphenyl)-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



L13 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
2005:592771 Document No. 143:166366 RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation. McDermott, Lee A.; Simcox, Mary; Higgins, Brian; Nevins, Tom; Kolinsky, Kenneth; Smith, Melissa; Yang, Hong; Li, Jia K.; Chen, Yingsi; Ke, June; Mallalieu, Navita; Egan, Tom; Kolis, Stan; Railkar, Aruna; Gerber, Louise; Luk, Kin-Chun (Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA). Bioorganic & Medicinal Chemistry, 13(16), 4835-4841 (English) 2005. CODEN: BMECEP. ISSN: 0968-0896. Publisher: Elsevier Ltd..
IT **774231-99-1P**, Ro 4383596

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and biol. evaluation of RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor in rodent models of angiogenesis upon oral administration)

RN 774231-99-1 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-1-[(1R,3R)-3-hydroxycyclopentyl]-3-(4-methoxyphenyl)-7-(phenylamino)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L13 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

2005:120672 Document No. 142:198094 Preparation of pyrimidopyrimidines as protein kinase inhibitors. Sim, Taebo; Lee, Hyun Soo; Ren, Pingda; Ding, Qiang; Wang, Xia; Uno, Tetsuo; Zhang, Guobao; Liu, Yi; Li, Bing; Li, Lintong; Gray, Nathaniel; You, Shuli (IRM LLC, Bermuda). PCT Int. Appl. WO 2005011597 A2 20050210, 148 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US24764 20040729. PRIORITY: US 2003-2003/PV491133 20030729.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005011597	A2	20050210	WO 2004-US24764	20040729
WO 2005011597	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **839705-52-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidines as protein kinase inhibitors)

RN 839705-52-1 CAPLUS

CN Benzamide, N-[3-[7-[[3-[(aminocarbonyl)amino]phenyl]amino]-1,4-dihydro-1-methyl-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



=> d 1-2 cbib pi hitstr

L13 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

1999:764041 Document No. 132:22971 Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors. Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel Conrad; Showalter, Howard Daniel Hollis; Toogood, Peter; Trumpp-Kallmeyer, Susanne A. (Warner-Lambert Co., USA). PCT Int. Appl. WO 9961444 A2 19991202, 133 pp. DESIGNATED STATES: W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US10187 19990510. PRIORITY: US 1998-86708 19980526; US 1999-126158 19990325.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961444	A2	19991202	WO 1999-US10187	19990510
	WO 9961444	A3	20000203		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2329703	AA	19991202	CA 1999-2329703	19990510
	AU 9940734	A1	19991213	AU 1999-40734	19990510
	AU 763839	B2	20030731		
	BR 9911590	A	20010213	BR 1999-11590	19990510
	EP 1080092	A2	20010307	EP 1999-924165	19990510
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

TR 200003429	T2	20010723	TR 2000-200003429	19990510
JP 2002516327	T2	20020604	JP 2000-550849	19990510
EE 200000706	A	20020617	EE 2000-706	19990510
NZ 508268	A	20040227	NZ 1999-508268	19990510
ZA 2000006536	A	20020211	ZA 2000-6536	20001110
BG 104960	A	20011031	BG 2000-104960	20001117
HR 2000000799	A1	20010630	HR 2000-799	20001120
NO 2000005928	A	20001123	NO 2000-5928	20001123
HK 1039483	A1	20040618	HK 2001-107828	20011108
US 2004044012	A1	20040304	US 2003-638848	20030811

IT **251370-13-5P 251370-14-6P 251370-15-7P**
251370-16-8P 251370-17-9P 251370-18-0P
251370-19-1P 251370-20-4P 251370-21-5P
251370-22-6P 251370-35-1P 251370-38-4P
251370-40-8P 251371-07-0P 251371-08-1P
251371-09-2P 251371-10-5P 251371-11-6P
251371-12-7P 251371-13-8P 251371-14-9P
251371-15-0P 251371-16-1P 251371-17-2P
251371-18-3P 251371-19-4P 251371-20-7P
251371-21-8P 251371-22-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation)

RN 251370-13-5 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-14-6 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(2-chloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-15-7 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-16-8 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxy-2-methylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-17-9 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxy-2,6-dimethylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-18-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-19-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-20-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-21-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-22-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-35-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-38-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-40-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251371-07-0 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-08-1 CAPLUS
CN Benzamide, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 251371-09-2 CAPLUS
CN Benzamide, 3-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 251371-10-5 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-11-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 251371-12-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-7-[[4-[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 251371-13-8 CAPLUS
CN Benzamide, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-14-9 CAPLUS
CN Benzamide, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-15-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-16-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-17-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-1-methyl-7-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-18-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 251371-19-4 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-20-7 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-21-8 CAPLUS
CN Benzaldehyde, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-22-9 CAPLUS
CN Benzaldehyde, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
2000:291041 Document No. 132:308352 Preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors. Harris, William; Hill, Christopher Huw; Smith, Ian Edward David (F. Hoffmann-La Roche A.-G., Switz.). PCT Int. Appl. WO 2000024744 A1 20000504, 109 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO

1999-EP7675 19991013. PRIORITY: GB 1998-23277 19981023; GB 1999-20044 19990824.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024744	A1	20000504	WO 1999-EP7675	19991013
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2347474	AA	20000504	CA 1999-2347474	19991013
	BR 9914677	A	20010717	BR 1999-14677	19991013
	EP 1123295	A1	20010816	EP 1999-953796	19991013
	EP 1123295	B1	20040929		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101102	T2	20020121	TR 2001-200101102	19991013
	JP 2002528455	T2	20020903	JP 2000-578314	19991013
	JP 3593035	B2	20041124		
	NZ 510760	A	20030829	NZ 1999-510760	19991013
	AU 769989	B2	20040212	AU 2000-10363	19991013
	AT 277931	E	20041015	AT 1999-953796	19991013
	ES 2228123	T3	20050401	ES 1999-953796	19991013
	RU 2256662	C2	20050720	RU 2001-113444	19991013
	US 6150373	A	20001121	US 1999-422451	19991021
	ZA 2001002652	A	20020930	ZA 2001-2652	20010330
	HR 2001000274	A1	20020630	HR 2001-274	20010412
	NO 2001001929	A	20010419	NO 2001-1929	20010419
	HK 1041483	A1	20041224	HK 2002-103084	20020424

IT **266312-86-1P 266312-87-2P 266312-88-3P**
266312-93-0P 266312-94-1P 266312-95-2P
266312-97-4P 266312-99-6P 266313-00-2P
266313-01-3P 266313-02-4P 266313-03-5P
266313-11-5P 266313-15-9P 266313-16-0P
266313-17-1P 266313-18-2P 266313-19-3P
266313-22-8P 266313-23-9P 266313-24-0P
266313-25-1P 266313-27-3P 266313-29-5P
266313-30-8P 266313-31-9P 266313-32-0P
266313-33-1P 266313-34-2P 266313-37-5P
266313-38-6P 266313-39-7P 266313-40-0P
266313-41-1P 266313-42-2P 266313-43-3P
266313-44-4P 266313-45-5P 266313-46-6P
266313-47-7P 266313-48-8P 266313-49-9P
266313-50-2P 266313-51-3P 266313-52-4P
266313-53-5P 266313-54-6P 266313-55-7P
266313-56-8P 266313-57-9P 266313-58-0P
266313-59-1P 266313-60-4P 266313-61-5P
266313-62-6P 266313-63-7P 266313-64-8P
266313-65-9P 266313-66-0P 266313-67-1P
266313-68-2P 266313-69-3P 266313-70-6P
266313-71-7P 266313-73-9P 266313-74-0P
266313-75-1P 266313-76-2P 266313-77-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)

RN 266312-86-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266312-87-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266312-88-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 266312-93-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)



RN 266312-94-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266312-95-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 266312-97-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(3-pyridinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 266312-96-3
CMF C30 H31 Cl2 N7 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 266312-99-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-fluorophenyl)amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-00-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-01-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-02-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-03-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-[[4-(2-hydroxyethyl)phenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-11-5 CAPLUS

CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-7-(1-naphthalenylamino)-1-phenyl- (9CI) (CA INDEX NAME)



RN 266313-15-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(2,6-dimethylphenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-16-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266313-17-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 266313-18-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 266313-19-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-phenyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-22-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(2,6-difluorophenyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-23-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-

(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-24-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,6-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266313-25-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-27-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-29-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-(2-cyclohexen-1-yl)-3-(2,6-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266313-30-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-31-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,5-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-32-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 266313-33-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-methoxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-34-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3,4-dihydro-3-(2-hydroxyphenyl)-1-methyl-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-37-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-

bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-38-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,6-dimethylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-39-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-[2-chloro-4-(trifluoromethyl)phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-40-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-41-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-chloro-6-methylphenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-42-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,5-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-43-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 266313-44-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(2-hydroxy-1,1-dimethylethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-45-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-1,1-dimethylethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-46-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX

NAME)



RN 266313-47-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-[(4-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 266313-48-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-49-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[3-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-50-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-51-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(aminomethyl)phenyl]-3-(2-bromophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-52-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-1-(1-naphthalenyl)-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-53-5 CAPLUS
CN Benzoic acid, 3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 266313-54-6 CAPLUS
CN Benzoic acid, 3-[[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 266313-55-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[(4-

ethoxyphenyl)amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)



RN 266313-56-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-57-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-[2-(methylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-58-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-59-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-60-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-61-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-(methylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-62-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-63-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-(cyclohexylmethyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-64-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[4-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-65-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[4-(hydroxymethyl)phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-66-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl-3-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 266313-67-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-(2-hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 266313-68-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-aminoethyl)phenyl]-3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266313-69-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-(dimethylamino)ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266313-70-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-phenyl- (9CI) (CA INDEX NAME)



RN 266313-71-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(2-amino-2-methylpropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-73-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-[1-(aminomethyl)-1-ethylpropyl]phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 266313-72-8
CMF C30 H30 Cl2 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 266313-74-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-[3-(3-aminopropyl)phenyl]-3-(2,6-dichlorophenyl)-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-75-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-1-[3-[2-(diethylamino)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-76-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-(4-morpholinyl)ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266313-77-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-7-(phenylamino)-1-[3-[2-(1-piperazinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **266314-05-0P 266314-38-9P 266314-39-0P**
266314-40-3P 266314-45-8P 266314-46-9P
266314-47-0P 266314-48-1P 266314-49-2P
266314-51-6P 266314-62-9P 266314-63-0P
266314-71-0P 266314-78-7P 266314-79-8P
266314-83-4P 266314-84-5P 266314-86-7P
266314-91-4P 266314-92-5P 266314-93-6P
266315-34-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidopyrimidinones as T-cell tyrosine kinase inhibitors)

RN 266314-05-0 CAPLUS
CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 266314-38-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-39-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,6-dimethylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-40-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-[2-chloro-4-(trifluoromethyl)phenyl]-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-45-8 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-1-[3-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-46-9 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-chloro-6-methylphenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-47-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-chloro-6-methylphenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-48-1 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,5-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-49-2 CAPLUS
CN Pyrimido[4,5-b]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-1-[3-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]-1,1-dimethylethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-51-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 266314-62-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[3-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 266314-63-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-bromophenyl)-3,4-dihydro-7-

(phenylamino)-1-[3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 266314-71-0 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[4-[3-(2-bromophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 266314-78-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-1-[3-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]phenyl]-3,4-dihydro-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-79-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-83-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-84-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 266314-86-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-[3-(2,4-dichlorophenyl)-3,4-dihydro-2-oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266314-91-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-[3-[2-[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]phenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 266314-92-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-[3-[2-[(methylsulfonyl)oxy]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 266314-93-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[3-[3-(2,4-dichlorophenyl)-7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3,4-dihydro-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 266315-34-8 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[3-[3-(2,6-dichlorophenyl)-3,4-dihydro-2-

oxo-7-(phenylamino)pyrimido[4,5-d]pyrimidin-1(2H)-yl]phenyl]propyl]- (9CI) (CA INDEX NAME)



=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.

STN INTERNATIONAL LOGOFF AT 13:48:23 ON 31 AUG 2005